What are your top takeaways in Thoracic Cancers from ASCO 2026?
While I believe there was a lot of exciting data presented at ASCO 2026 and it is very challenging to limit my favorite abstracts to just three, I believe the following three abstracts were most impactful:
ABSTRACT 8000: ECOG-ACRIN EA5142
This was a very important presentation and reinforces my growin...
- LIBRETTO-432, which investigated 3 years of adjuvant selpercatinib versus placebo in Stage IB-IIIA RET-fusion + NSCLC after definitive surgery or radiation followed by systemic chemotherapy (as applicable). The primary analysis population was based on 109 patients with stage II or IIIA NSCLC who we...
- Abstract 8008 – ABBV-706 SEZ6 ADC in relapsed SCLC - SEZ6 appears to be a good target, as it is very commonly expressed in SCLC. Anti-SCLC activity of single-agent therapy in a good-sized cohort of relatively heavily pretreated patients (n=124) was encouraging, with an ORR of 56% and a median OS of...
- LBA8500 - Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28). WU-KONG28 (NCT05668988) was a multinational randomized phase 3 study comparing sunvozertin...
ASCO 2026 included a wealth of important trials for lung cancer. I will focus on moving the needle for targeted therapy with my top 3 below:
- LIBRETTO-432 showed a highly significant improvement in DFS with selpercatinib following resection for stage II-IIIA RET fusion-positive NSCLC. The results led...
- EGFR- It is “uncommon” to see such nice updates on atypical EGFR mutations and EGFR exon 20 insertions. CHRYSALIS-2 cohort of patients with atypical EGFR mutations treated with amivantamab/lazertinib now provides an OS update following prior eye-popping PFS results of 19 months or so. Very impressi...
- CROWN trial 7-year data: This update shows that the activity of lorlatinib continues to be very durable, which continues to support its role as a frontline therapy for metastatic ALK NSCLC. However, the toxicities and side effects remain challenging, and we need to investigate what supportive thera...
At ASCO 2026, many important studies in Lung cancer were presented, but these three are my top picks.
- The first is the LIBRETTO-432 trial, which is a double-blind, placebo-controlled phase III trial in which patients with stage IB-IIIA RET+ NSCLC after definitive local therapy (Surgery or radiothera...
At the ASCO 2026 meeting, two important trials on NSCLC were presented in the Plenary Session that may have a significant impact on future management in these patient populations.
Phase III LIBRETTO trial- 432: Presented in this year's ASCO Plenary Session. This trial included NSCLC with a RET fusio...